ampakine
Small moleculeexperimental
Ampakines or AMPAkines are a subgroup of AMPA receptor positive allosteric modulators with a benzamide or closely related chemical structure. They are also known as "CX compounds". Ampakines take their name from the AMPA receptor (AMPAR), a type of ionotropic glutamate receptor with which the ampakines interact and act as positive allosteric modulators (PAMs) of. Although all ampakines are AMPAR PAMs, not all AMPAR PAMs are ampakines. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 1996 (NCT00001662)
Timeline
1990s
- Jan 1, 1996
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAmpakine ↗
Also known as
- ampakine
- ampakine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03375021 | Phase 2 | Jul 19, 2005 | New York University, RespireRx |
| NCT00235352 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2002 | North Suffolk Mental Health Association, RespireRx |
| NCT00001662 | Phase 2 | Dec 1, 1996 | National Institute of Neurological Disorders and Stroke (NINDS) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RespireRx | For profit | 2 | 1 | 2 | 2002 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 1996 |
| New York University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| North Suffolk Mental Health Association | Academic/Hospital | 1 | 1 | 1 | 2002 |
4 organizations
Page 1 / 1